Patents by Inventor Ursula Klingmuller

Ursula Klingmuller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREDICTION-METHOD OF MORTALITY DUE TO TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS
    Publication number: 20180217166
    Abstract: The present invention pertains to the diagnosis of a high risk of mortality or other adverse events in a patient suffering from anemia, for example anemia caused by chemotherapy, cancer or chronic inflammation such as chronic kidney disease (CKD). The invention provides means to diagnose a patient who receives Erythropoiesis Stimulating Agents (ESA) and suffer from an adverse event if the treatment with the ESA is continued. Based on the herein disclosed methods, the clinician will be able to diagnose the prevalence of a fatal event and adjust the treatment of the anemia in the patient accordingly.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 2, 2018
    Inventors: Agustin Rodriguez Gonzalez, Marcel Schilling, Bernhard Steiert, Jens Timmer, Ursula Klingmüller
  • Peptide which binds SH.sub.2 domains of protein tyrosine phosphatase SH-PTP1
    Patent number: 5659012
    Abstract: Novel assays for identifying agents which alter the effect of erythropoietin on proliferation of erythroid cells and agents identified thereby. Novel peptide comprising the erythropoietin receptor binding site for SH-PTP1.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: August 19, 1997
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Ursula Klingmuller, Stephen Michnick, Benjamin G. Neel, Ulrike Lorenz, Harvey F. Lodish